In a cohort of 148 HCC patients, the expression of the MEK1–SIRT1 pathway was strongly correlated with tumor size, vascular and capsular invasion, clinical tumor stage, and poor prognosis (46). The gene discussed is MAP2K1; the disease is hepatocellular carcinoma.